David W. Cescon

home / authors / david-w-cescon

Articles

11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756

Fatima Cardoso;Joyce O’Shaughnessy, MD;Heather McArthur, MD, MPH;Peter Schmid, MD;Javier Cortés, MD;Nadia Harbeck, MD, PhD;Melinda L. Telli, MD;David W. Cescon;Peter A. Fasching;Zhimin Shao;Delphine Loirat;Yeon Hee Park;Manuel Gonzalez Fernandez;Gábor Rubovszky;Seock-Ah Im;Rina Hui;Toshimi Takano;Fabrice André;Hiroyuki Yasojima;Zhenzhen Liu;Yu Ding;Liyi Jia;Vassiliki Karantza;Konstantinos Tryfonidis;Aditya Bardia, MD, MPH
August 18th 2024
17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

Stephanie L. Graff, MD;Peter Schmid, MD;Massimo Cristofanilli, MD;David W. Cescon;Tina Hovey;Karson Tse;Petra Vuković;Joyce O’Shaughnessy, MD
August 11th 2024
30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Komal Jhaveri;Seock-Ah Im;Senia Pernas;Michelino De Laurentiis;Shusen Wang;Noelia Martínez Jañez;Giuliano Borges;David W. Cescon;Masaya Hattori;Yen-Shen Lu;Erika P. Hamilton, MD;Qingyuan Zhang;Junji Tsurutani;Kevin Kalinsky, MD, MS;Lu Xu;Neelima Denduluri;Binghe Xu;Barbara Pistilli
July 20th 2024

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: September 8th 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: July 16th 2011 | Updated: September 8th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Regardless of T790M status, lazertinib hindered the progression of intracranial metastases after unsuccessful EGFR TKI treatment in patients with EGFR-mutated NSCLC.
Published: August 29th 2024 | Updated: September 8th 2024
Lazertinib Shows Encouraging Intracranial ORR in EGFR NSCLC with CNS Metastases